NDA filed for alectinib

On September 9 a new drug application was filed by Genentech for Alectinib. The FDA granted priority review status. It already has breakthrough therapy status.

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Lung cancer, Potential Treatments, Regulatory applications & approvals. Bookmark the permalink.

Leave a Reply